secwatch.observer — SEC 8-K summary
======================================

Issuer:     Orchestra BioMed Holdings, Inc. (OBIO)
CIK:        0001814114
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001104659-26-002752
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Orchestra BioMed to receive up to $21M from Haemonetics' acquisition of Vivasure
--------------------------------------------------------------------------------

- Expects $11M in 2026 proceeds: ~$5M upfront + ~$6M first milestone payment.
- Remaining up to $10M from future revenue earnouts based on milestone achievement.
- Vivasure's PerQseal Elite received CE Mark and filed PMA with FDA; 0% major complications at 30 days.
- Haemonetics closed acquisition on January 9, 2026; OBIO was strategic holder since formation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1814114/000110465926002752/0001104659-26-002752-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1814114/000110465926002752/tm262832d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-002752

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer